Incyte | INCY - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Agenus USD 34.2M 4.61M 2025-12
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
Alnylam Pharmaceuticals USD 825M 4.3M 2026-03
Amgen USD 6.89B 415M 2025-12
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
Biogen USD 1.82B 169.5M 2026-03
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
Bristol-Myers Squibb USD 8.41B 381M 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
Exelixis USD 572.18M 7M 2025-12
Gilead Sciences USD 6.31B 106M 2025-12
Incyte USD 1.17B 217.51M 2026-03
Ionis Pharmaceuticals USD 243M 48M 2026-03
MacroGenics USD 31.11M 30.14M 2025-12
Merck USD 10.85B 2.57B 2025-12
Moderna USD -566M 792M 2026-03
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Neurocrine Biosciences USD 787.9M 7M 2025-12
Novartis USD 10.07B 184M 2026-03
Novartis USD 10.82B 694M 2025-09
Pfizer USD 12.28B 8.74B 2025-12
PTC Therapeutics USD 148.38M 39.31M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 2.94B 363.7M 2026-03
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
Vertex Pharmaceuticals USD 2.6B 121.7M 2026-03